Payment overview · 2025
General Payments
$1,480.48
79 reported records · 19 companies
Healthcare provider profile · identity verified
Emily Lynn Murphy, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · NEOSHO, MO · NPI 1982206066
Verified facts
What the public records show
CMS Open Payments records show Emily Lynn Murphy, ARNP received $1,480.48 in general payments during 2025 across 79 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rexulti.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $269.11 | 18.2% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $208.48 | 14.1% | 16 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $174.98 | 11.8% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $123.64 | 8.3% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $107.73 | 7.3% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $104.17 | 7.0% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $81.57 | 5.5% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $63.09 | 4.3% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $62.35 | 4.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $59.85 | 4.0% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.66 | 3.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.24 | 2.8% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $33.27 | 2.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.72 | 2.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.42 | 1.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.40 | 1.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.30 | 1.0% | 1 | 2025 |
| Exeltis, USA Inc. | Unresolved — no canonical attribution shown | $13.50 | 0.9% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $12.00 | 0.8% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,480.48 | 79 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $230.59 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $174.06 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $168.80 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $167.58 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $157.25 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $157.25 | 10 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $104.17 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $100.45 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $91.20 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $87.95 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $81.57 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $80.82 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $62.35 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $49.48 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $47.66 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.69 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $33.27 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.13 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $30.72 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| SLYND Normalized: slynd |
Drug | Exeltis, USA Inc. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $12.00 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $12.00 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 33 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Tramadol Hcl | Tramadol Hcl | 120 | 32 |
| Atorvastatin Calcium | Atorvastatin Calcium | 115 | 37 |
| Gabapentin | Gabapentin | 114 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 90 | 34 |
| Montelukast Sodium | Montelukast Sodium | 89 | 22 |
| Omeprazole | Omeprazole | 85 | 25 |
| Prednisone | Prednisone | 84 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 82 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 75 | 70 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 66 | 61 |
| Lisinopril | Lisinopril | 66 | 27 |
| Losartan Potassium | Losartan Potassium | 66 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 24 |
| Metformin Hcl | Metformin Hcl | 63 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 59 | 21 |
| Sertraline Hcl | Sertraline Hcl | 57 | 15 |
| Meloxicam | Meloxicam | 53 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 53 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 22 |
| Trazodone Hcl | Trazodone Hcl | 40 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 15 |
| Furosemide | Furosemide | 39 | 20 |
| Ozempic | Semaglutide | 33 | 11 |
| Potassium Chloride | Potassium Chloride | 32 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 31 | 14 |
| Trulicity | Dulaglutide | 31 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 30 | 11 |
| Alprazolam | Alprazolam | 29 | suppressed |
| Azithromycin | Azithromycin | 29 | 28 |
| Carvedilol | Carvedilol | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 20 |
| Topiramate | Topiramate | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 14 |
| Cephalexin | Cephalexin | 16 | 13 |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 15 |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Simvastatin | Simvastatin | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Allopurinol | Allopurinol | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,480.48 · 79 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, GEMTESA, JARDIANCE, Kerecis GraftGuide, Kerecis SurgiClose, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, SLYND, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error